JUN and plasma cell myeloma: In several cancer cell lines, including multiple myeloma (MM) and mantle cell lymphoma (MCL), treatment with bortezomib resulted in NF-κB pathway inhibition, cleavage of Mcl-1 and prompted c-Jun/AP-1 pathway [207,208].